Startupticker.ch’s Post

Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio Boehringer Ingelheim acquires Saiba Animal Health AG, strengthens animal health RnD pipeline Boehringer Ingelheim has said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address chronic diseases in pets. With the acquisition, Boehringer Ingelheim strengthens its animal health research and development (R&D) pipeline, specifically in the fast-growing pet therapeutics category. As life expectancy for pets increases, so does the need for effective treatment of debilitating diseases, according to the release. Saiba Animal Health’s innovative technology platform uses a therapeutic vaccine approach, which is designed to create an immune response, targeting chronic diseases such as allergy, inflammation and pain. The therapeutic vaccines incorporate virus-like particles to induce the animal’s immune system. They produce neutralizing antibodies against the animal’s own disease-causing proteins. This approach may result in a longer duration of action, better treatment outcomes, and increased pet owner convenience and compliance. The acquisition follows several development and licensing collaborations between Boehringer Ingelheim and Saiba Animal Health. Those collaborations advanced multiple species-specific product candidates, based on Saiba Animal Health’s technology platform, aiming to improve the management of chronic diseases in companion animals. Dr. Gary Jennings, CEO of Saiba Animal Health, said, “We are thrilled that our long-term partnership with Boehringer Ingelheim has evolved to this agreement. Joining forces will pave the way for a whole new class of therapeutic medicines for pets, with a true impact on the lives of animals and their owners.” Terms of the transaction were not disclosed. Stifel acted as exclusive financial advisor to Saiba Animal Health for the transaction. #BoehringerIngelheim #BoehringerIngelheimnews #SaibaAnimalHealth #acquisition

Veterinary Reference Laboratory Market worth USD 7.8 billion by 2029 Download PDF Brochure: https://lnkd.in/dciWYFHc The size of global veterinary reference laboratory market in terms of revenue was estimated to be worth $4.6 billion in 2024 and is poised to reach $7.8 billion by 2029, growing at a CAGR of 11.2% from 2024 to 2029. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 IDEXX Zoetis Neogen Corporation Laboklin - Labor für klinische Diagnostik GmbH & Co. KG & Co. KG VetLab Virbac Thermo Fisher Scientific Vaxxinova Texas A&M Veterinary Medical Diagnostic Lab (TVMDL) University of Minnesota Iowa State University QML Vetnostics Greencross Vets ProtaTek International, Inc. Animal and Plant Health Agency National Veterinary Services Laboratories Washington Animal Disease Diagnostic Lab (WADDL) Colorado State University The Pirbright Institute Kansas State University 𝐎𝐭𝐡𝐞𝐫 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐥𝐨𝐛𝐚𝐥𝐥𝐲 Antech Diagnostics National Veterinary Research Institute Vom AVACTA ANIMAL HEALTH LIMITED PALS - Pet and Animal Lovers Service Clinical Pathology Laboratory Phoenix Central Laboratory For Veterinarians, Inc. Northwest Zoopath Heska Australia NationWide Laboratories Scanelis Veterinary Diagnostic Services Laboklin - Labor für klinische Diagnostik GmbH & Co. KG Antech Diagnostics UK Vetnostics Pathology Davis-Thompson Foundation

Dental procedures are among the most frequently performed in primary care veterinary clinics, yet there are currently no universally applied guidelines for antimicrobial usage (AMU) in companion animal dentistry. As part of Mars Veterinary Health's commitment to pharmaceutical stewardship, we teamed up with UC Davis School of Veterinary Medicine to study patterns of AMU in canine and feline dentistry within US-based primary care practices with a goal of understanding how evidence-based AMU guidance may help preserve antimicrobial agent efficacy in the face of increasing antimicrobial resistance. Mars Veterinary Health's Dr. Ian Battersby, Dr. JoAnn Morrison, and Nate Spofford were among the co-authors of the resulting peer-reviewed article published in PLOS One. You can read more about the study and its conclusions at the links below. Overview on the Banfield Exchange: https://lnkd.in/gSHUnGGq Full article in PLOS One: https://lnkd.in/g-eduuPg

🐶 Interesting Study On Basophilia in Dogs 🐶 Basophilia is a rare hematologic finding in dogs. The research on this interesting study aimed to describe the hematologic and clinical characteristics of dogs with moderate-to-marked basophilia. #Veterinary #Science #Research CBC reports with blood smear examinations from dogs presented to the North Carolina State University Veterinary Teaching Hospital were retrospectively reviewed for basophilia. The study also investigated differences between dogs with marked basophilia versus those with moderate basophilia, as well as between dogs in the basophilia group with and without concurrent eosinophilia. 🐕 Read more: https://ow.ly/FmU650RXncI #veterinary33 #veterinaryjournal #veterinaryarticle #alwayslearning #scientificjournals #scientificarticles

🔎 EIDS are very pleased to be assisting final year vet student Katie Riley from Department of Veterinary Medicine, University of Cambridge with a valuable research project looking to collate first hand feedback from UK veterinary surgeons about their experience with, attitudes to and use of equine strangles vaccines, now that Strangvac (Dechra) a novel fusion protein vaccine is available to vets in the UK and across Europe. 📝This independent survey should take no more than 10 minutes to complete and whether or not you have yet had any experience with Strangvac, your responses will be invaluable for EIDS to gain insights into the practicalities of implementing vaccination against strangles in equine practice, thereby better informing future prevention and control of this most impactful equine infectious disease. If you are a UK veterinary surgeon, please do take the time to complete this survey, which is available through the following link https://lnkd.in/edxRtYRW The survey can also be accessed through the British Equine Veterinary Association's website survey page (7th survey down) at https://lnkd.in/eMXB_RyH #EquineHealth #EquineVet #VeterinaryScience #UniversityOfCambridge #VeterinaryEpidemiology #InfectiousDisease #EquineInfectiousDiseaseSurveillance #EquineInfectiousDisease

Ms Truyen, a student at the University of Veterinary Medicine in Hannover, Germany, will receive a grant of US$15,000 to support her research, which aims to gain a better understanding of how canine distemper virus (CDV)-specific maternal antibodies are transmitted from mothers to puppies in order to inform future CDV vaccine strategies. Read the full story here: https://lnkd.in/eBpTncjs

This is a nice local newspaper article which is pointing to a general dilemma when talking about non-animal methods in regulatory processes. For understandable ethical and humane reasons animal rights groups have petioned the FDA to move faster in approving non-animal testing. On the other side the FDA, while supporting industry efforts to develop and use alternative methods, needs evidence that their regulatory decisions, i.e. the benefit-risk assessment for new drug candidates, can in fact be based on such novel methods. In this context, it is important to note that the FDA Modernization Act 2.0, passed in 2022, freed the FDA from requiring animal tests, i.e. it gave the FDA the option to accept non-animal tests, but didn’t explicitly require FDA to give them priority. To speed up the process, an updated version, the FDA Modernization Act 3.0, is now going further by requiring FDA to establish a process to qualify the new testing methods and expedite drug applications that incorporate non-animal approaches. The updated bill is expected to facilitate the development, qualification, and adoption of testing methods that could reduce or possibly even replace the use of animals in nonclinical testing. From my perspective it is important to note that the FDA Modernization Act 3.0 makes it clear from the very beginning that the reduction and replacement of animals must not be seen as an isolated or independent target in nonclinical research but that there is in fact a high need to improve the predictivity of nonclinical testing methods and to reduce the development time for a biological product or other drug. The low likelyhood of technical success remains the biggest challenge for all R&D organizations in pharmaceutical industry but there is hope that novel (non-animal) technologies along with artificial intelligence/machine learning approaches may lead to better predictions and thereby better outcomes for patients which must be the most important and ultimate goal of any activity. A full alignment and full support from all stakeholders is needed to make this happen. While it is clear that it may still take some time and huge efforts before novel alternative methodologies can be used to fully replace an intact organism, the use of such models to answer a particular question can already be justified now. I am convinced that regulators are open for such discussions. In this context it is encouraging to see that small companies like Lena Biosciences with their power to innovate are offering already now solutions to particular questions and on the long run they may play an important role in the transformation process. Jelena Vukasinovic James T Shoemaker Lena Biosciences

📃Scientific paper: Building the European Antimicrobial Resistance Surveillance network in veterinary medicine (EARS-Vet) Abstract: International audience; Antimicrobial resistance (AMR) should be tackled through a One Health approach, as stated in the World Health Organization Global Action Plan on AMR. We describe the landscape of AMR surveillance in the European Union/European Economic Area (EU/EEA) and underline a gap regarding veterinary medicine. Current AMR surveillance efforts are of limited help to veterinary practitioners and policymakers seeking to improve antimicrobial stewardship in animal health. We propose to establish the European Antimicrobial Resistance Surveillance network in Veterinary medicine (EARS-Vet) to report on the AMR situation, follow AMR trends and detect emerging AMR in selected bacterial pathogens of animals. This information could be useful to advise policymakers, explore efficacy of interventions, support antimicrobial stewardship initiatives, (re-)evaluate marketing authorisations of antimicrobials, generate epidemiological cut-off values, assess risk of zoonotic AMR transmission and evaluate the burden of AMR in animal health. EARS-Vet could be integrated with other AMR monitoring systems in the animal and medical sectors to ensure a One Health approach. Herein, we present a strategy to establish EARS-Vet as a network of national surveillance systems and highlight challenges of data harmonisation and bias. Strong political commitment at national and EU/EEA levels is required for the success of EARS-Vet. Continued on ES/IODE ➡️ https://etcse.fr/3iVj ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Our community can enjoy three exciting new veterinary CPD/CE webinars this week! 💻🌟 Wednesday 10th January - “An Overview of Equine Oncology 2024” - Jamie Prutton. With thanks to Baileys Horse Feeds.🐴 Oncology is infrequently discussed due to the smaller number of cases in the equine population. During this webinar an approach to the oncological case will be discussed, how to ensure the correct diagnosis is made and what the treatment options are. Wednesday 10th January - “Ovine Caesarean Sections: think beyond your surgical technique” - David Charles.🐑 If you’ve ever wondered; Which antibiotic is most appropriate? What can I do to improve survival rates? What about anaesthesia and analgesia? Does surgical gloving matter? Then this webinar is for you! Thursday 11th January - “Cutaneous adverse drug reactions” - Anita Patel. 🐶 With thanks to Simply Vets. Adverse reactions can occur to any drug, some are more common than others. This webinar discusses cutaneous reactions to drugs that are commonly used in small animal practice. With an Unlimited Membership, you will have access to ALL of the sessions, plus the other 2,500+ webinars in our huge library. Why not start your 7-day trial today and get stuck in! 🌟 #TheWebinarVet #VeterinaryMedicine #OnlineLearning

Attending ACVIM in June? Learn more about best practices in veterinary sustainability with VCA Animal Hospitals' Diccon Westworth BVSc (Hons), DACVIM (Neurology), NCT at his upcoming session! #sustainability #ProudlyMars